Source comparison
Modified GRF Same as CJC-1295 No DAC: [Peptide Identity] Comparison
The table below clarifies what's identical, what differs from the DAC version, and what researchers should verify before designing protocols. Amino Acid Sequence Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-
This comparison does not assign a generated winner or score.
- The table below clarifies what's identical, what differs from the DAC version, and what researchers should verify before designing protocols.
- Amino Acid Sequence
- Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
- Identical to Modified GRF (1-29)
- Same base sequence + DAC linker (maleimidoproprionic acid modification)
- Modified GRF and CJC-1295 no DAC are molecularly identical. The DAC version is structurally distinct
- Molecular Weight
- 3367.97 g/mol
- 3647 g/mol (base + linker)
- Weight confirms identity: Modified GRF and no-DAC are identical, DAC version is heavier
- Plasma Half-Life
- ~30 minutes
- ~8 days (albumin binding extends clearance)
- Short half-life for both Modified GRF and no-DAC requires multiple daily dosing; DAC version is once-weekly
- Receptor Target
- GHRH-R (growth hormone-releasing hormone receptor)
- GHRH-R
- All three peptides bind the same receptor. Activity difference is pharmacokinetic, not pharmacodynamic
- Typical Research Dose
- 100–200 mcg SC, 2–3× daily
- 1–2 mg SC, once weekly
- Dosing frequency is the key operational difference between short-acting (Modified GRF/no-DAC) and long-acting (DAC) protocols
- Peak GH Response Time
- 30–45 minutes post-dose
- 2–4 hours post-dose (sustained elevation over days)
- Fast peak confirms pulsatile GH release for Modified GRF and no-DAC; DAC produces steady-state elevation